Literature DB >> 9813406

Elevated plasma levels of homocysteine in Parkinson's disease.

W Kuhn1, R Roebroek, H Blom, D van Oppenraaij, H Przuntek, A Kretschmer, T Büttner, D Woitalla, T Müller.   

Abstract

Significantly elevated plasma levels of homocysteine, but not cysteine and cysteinylglycine, were found in treated parkinsonian patients compared to controls. Elevated levels of homocysteine may be either caused by an unknown endogenous metabolic disturbance or by antiparkinsonian treatment, because no association to severity or duration of disease was found. Based on the results of this study one may speculate that homocysteine may be an independent risk factor for vascular disease in Parkinson's disease.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9813406     DOI： 10.1159/000007984

Source DB:  PubMed          Journal:  Eur Neurol        ISSN： 0014-3022            Impact factor:   1.710


  35 in total

1.  The influence of L-dopa on methylation capacity in aromatic L-amino acid decarboxylase deficiency: biochemical findings in two patients.

Authors:  C Bräutigam; R A Wevers; K Hyland; R K Sharma; A Knust; G F Hoffman
Journal:  J Inherit Metab Dis       Date:  2000-06       Impact factor: 4.982

2.  Homocysteine and folate deficiency sensitize oligodendrocytes to the cell death-promoting effects of a presenilin-1 mutation and amyloid beta-peptide.

Authors:  Kirk J Pak; Sic L Chan; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

3.  The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats.

Authors:  E Nissinen; H Nissinen; H Larjonmaa; A Väänänen; T Helkamaa; I Reenilä; P Rauhala
Journal:  J Neural Transm (Vienna)       Date:  2004-12-22       Impact factor: 3.575

4.  Homocysteine alters glutamate uptake and Na+,K+-ATPase activity and oxidative status in rats hippocampus: protection by vitamin C.

Authors:  Fernanda R Machado; Andréa G K Ferreira; Aline A da Cunha; Bárbara Tagliari; Ben Hur M Mussulini; Susana Wofchuk; Angela T S Wyse
Journal:  Metab Brain Dis       Date:  2011-02-03       Impact factor: 3.584

Review 5.  Vascular complications of cystathionine β-synthase deficiency: future directions for homocysteine-to-hydrogen sulfide research.

Authors:  Richard S Beard; Shawn E Bearden
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-22       Impact factor: 4.733

6.  Levodopa reduces risk factors for vascular disease in parkinsonian patients.

Authors:  Giulio Scigliano; Gabriele Ronchetti; Floriano Girotti; Massimo Musicco
Journal:  J Neurol       Date:  2008-05-30       Impact factor: 4.849

Review 7.  Neurodegenerative disease and obesity: what is the role of weight loss and bariatric interventions?

Authors:  Hutan Ashrafian; Leanne Harling; Ara Darzi; Thanos Athanasiou
Journal:  Metab Brain Dis       Date:  2013-05-08       Impact factor: 3.584

8.  Possible treatment concepts for the levodopa-related hyperhomocysteinemia.

Authors:  Thomas Müller
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-09-09

9.  Vitamin B12-impaired metabolism produces apoptosis and Parkinson phenotype in rats expressing the transcobalamin-oleosin chimera in substantia nigra.

Authors:  Carlos Enrique Orozco-Barrios; Shyue-Fang Battaglia-Hsu; Martha Ligia Arango-Rodriguez; Jose Ayala-Davila; Celine Chery; Jean-Marc Alberto; Henry Schroeder; Jean-Luc Daval; Daniel Martinez-Fong; Jean-Louis Gueant
Journal:  PLoS One       Date:  2009-12-21       Impact factor: 3.240

10.  Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.

Authors:  Eliseu Felippe dos Santos; Estela Natacha Brandt Busanello; Anelise Miglioranza; Angela Zanatta; Alethea Gatto Barchak; Carmen Regla Vargas; Jonas Saute; Charles Rosa; Maria Júlia Carrion; Daiane Camargo; André Dalbem; Jaderson Costa da Costa; Sandro René Pinto de Sousa Miguel; Carlos Roberto de Mello Rieder; Moacir Wajner
Journal:  Metab Brain Dis       Date:  2009-03-18       Impact factor: 3.584
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.